Study Evaluating MST-997 in Advanced Malignant Solid Tumors

Stopped early · Phase 1

Conditions studied: Neoplasms

In brief

MST-997 is a taxane analog with the potential to treat subjects with a variety of tumor types. Preclinical data demonstrated that MST-997 inhibited tumor growth when administered intravenously (IV). This phase 1 dose escalation study is designed to evaluate the safety and tolerability of if IV MST-997 formulated in Polysorbate 80 Diluent can be safely administered on a weekly basis.

Key facts

Study ID

NCT00277836

Run by

Wyeth is now a wholly owned subsidiary of Pfizer

People needed

60

Last updated by the study team

2006-12-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented diagnosis of malignant solid tumor with measurable disease
• Life expectancy of at least 12 weeks
• ECOG (Eastern Cooperative Oncology Group) performance status of 0,1,or 2

You may not qualify if…

• Recent major surgery, radiation therapy or anti-cancer treatment
• History of any other prior malignancy within last 5 years

Where it is running

• Study site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.